Antibody Engineering
Our laboratory is working on the development of novel antibody therapeutics. In particular, we are interested in the engineering of human antibody fragments, which are considerably smaller than current monoclonal antibodies and in the mechanisms of immunomodulation by intravenous immunoglobulin. Human antibody fragments (such as domain antibodies) can be generated by genetic engineering technology, completely bypassing the use of animals. Thus, these fragments can be produced in large quantities in bacteria and open up promising new routes for non-intravenous applications, imaging and therapy. We are applying our technology to targets in cancer and inflammatory diseases.
Staff
Dr Carol Lee |
Dr Ellen de Leon |
|
Kip Dudgeon |
||
Danyal Butt |
||
| Emeritius Professor Antony Basten AO FAA FTSE
also holds an appointment in the antibody engineering and
therapeutics group See Professor Basten's Profile |
